Appointment dossier — Ovarian Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Cancer
- Olaparib — Human evidence · 2 positive · PMID 33743851, 30345884, 39013199
- Bevacizumab — Human evidence · 1 positive · PMID 22529265, 39013199
- Relacorilant — Human evidence · 1 positive / 1 negative-mixed · PMID 40473448, 39032926, 37364223
- Mirvetuximab Soravtansine — Human evidence · 0 positive / 1 negative-mixed · PMID 39631181
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Carboplatin — Review evidence · 0 positive · PMID 39013199
- Cisplatin — Review evidence · 0 positive · PMID 39013199
- Gemcitabine — Review evidence · 0 positive · PMID 39013199
- Liposomal Doxorubicin — Review evidence · 0 positive · PMID 39013199
- Niraparib †Rx — Review evidence · 0 positive · PMID 39013199
- Paclitaxel — Review evidence · 0 positive · PMID 39013199
- Tamoxifen — Review evidence · 0 positive · PMID 39013199
- Topotecan — Review evidence · 0 positive · PMID 39013199
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06394492 · Phase 3 — SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (China)
- NCT06476184 · Phase 3 — Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery (France)
- NCT06971744 · Phase 2 — Autophagy Maintenance (AUTOMAIN) (United States)
- NCT03412877 · Phase 2 — Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (United States)
- NCT07033819 · Phase 2 — Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib (China)
- NCT07617753 · Phase 1 / Phase 2 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (China)
- NCT06430541 · Phase 1 — Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence (United States)
- NCT05942300 · Phase 1 — CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (United States)
- NCT06840886 · Phase 1 — A Study of PHST001 in Advanced Solid Tumors (United States)
- NCT04282044 · Phase 1 — Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies (United States)
- NCT05080946 · Early Phase 1 — Using Aspirin to Improve Immunological Features of Ovarian Tumors (United States)
- NCT07361471 — Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy (France)
- NCT05027828 — CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer (China)
- NCT05051722 — Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer (United States)
- NCT07318051 — Sample Collection for Ongoing Research and Product Evaluation Study (United States)
- NCT06232122 — Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer (Taiwan)
- NCT01034033 — Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples (United States)
- NCT01441089 — Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis (United States)
Most-relevant first: trials that name Ovarian Cancer, then broader trials you may still qualify for. 776 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Niraparib †Rx × CYP1A2 inhibitors (high-stakes) — Monitor (low)
- Niraparib †Rx × P-gp substrates (high-stakes) — Monitor (low)
- Niraparib †Rx × Bevacizumab — Synergize (low)
Questions to ask your oncologist
- I've read that Olaparib has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Bevacizumab has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Relacorilant has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT06394492), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?